Atlas Trials

Nektar Therapeutics

39 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Nektar Therapeutics

RecordFirmDate
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (NCT07711418)Nektar Therapeutics2026-08-01
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (NCT07690371)Nektar Therapeutics2026-06-29
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) (NCT06340360)Nektar Therapeutics2024-04-02
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT06136741)Nektar Therapeutics2023-11-15
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma (NCT05664217)Nektar Therapeutics2022-12-23
A Phase I Study of LY3471851 in Healthy Participants (NCT05565729)Nektar Therapeutics2022-10-05
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) (NCT04969861)Nektar Therapeutics2022-03-09
A Single-Dose Study of LY3471851 in Healthy Participants (NCT04998487)Nektar Therapeutics2021-08-16
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT04677179)Nektar Therapeutics2021-03-22
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 (NCT04646044)Nektar Therapeutics2020-11-13
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (NCT04616196)Nektar Therapeutics2020-10-30
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (NCT04410445)Nektar Therapeutics2020-07-27
A Study of LY3471851 in Participants With Eczema (NCT04081350)Nektar Therapeutics2019-12-04
A Study of LY3471851 in Participants With Psoriasis (NCT04119557)Nektar Therapeutics2019-11-26
A Study of LY3471851 in Healthy Participants (NCT04133116)Nektar Therapeutics2019-10-29
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (NCT04136756)Nektar Therapeutics2019-10-07
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab (NCT04955262)Nektar Therapeutics2019-08-01
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (NCT03785925)Nektar Therapeutics2019-04-29
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) (NCT03729245)Nektar Therapeutics2018-12-18
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users. (NCT03802227)Nektar Therapeutics2018-10-22
A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) (NCT03556007)Nektar Therapeutics2018-04-18
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (NCT03435640)Nektar Therapeutics2018-03-15

Track Nektar Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.